 |
 |

Modeling Axonal Degeneration Within the Anterior Visual SystemImplications for Demonstrating Neuroprotection in Multiple Sclerosis
Elliot M. Frohman, MD, PhD;
Fiona Costello, MD;
Olaf Stüve, MD;
Peter Calabresi, MD;
David H. Miller, MD;
Simon J. Hickman, MD;
Robert Sergott, MD;
Amy Conger, BA;
Amber Salter, MPH;
Kimberly H. Krumwiede, MA;
Teresa C. Frohman, BA;
Laura Balcer, MD;
Robert Zivadinov, MD, PhD
Arch Neurol. 2008;65(1):26-35.
A major objective in multiple sclerosis therapeutics is to develop strategic targeting of specific injury pathways to provide neuroprotection and potentially even restoration. Here we underscore the potential utility of the anterior visual system for the purpose of modeling neuroprotection in response to novel therapies.
Author Affiliations: Departments of Ophthalmology (Dr E. M. Frohman), Neurology (Drs E. M. Frohman and Stüve and Mss Conger, Salter, and T. C. Frohman), and Biomedical Communications (Ms Krumwiede), University of Texas Southwestern Medical Center at Dallas; Division of Neurology, Department of Medicine, and Department of Ophthalmology, University of Ottawa, Ottawa, Ontario, Canada (Dr Costello); Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland (Dr Calabresi); NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, London, England (Drs Miller and Hickman); Department of Ophthalmology, Wills Eye Clinic, Thomas Jefferson University (Dr Sergott) and Departments of Neurology and Ophthalmology, University of Pennsylvania (Dr Balcer), Philadelphia; and Department of Neurology, Buffalo Neuroimaging Analysis Center, The Jacobs Neurological Institute, State University of New York at Buffalo (Dr Zivadinov). Dr Costello is now with the Department of Neurosciences, The University of Calgary, Calgary, Alberta, Canada.
|